Cambridge, UK cambiotechnology firm Shift Bioscience, has secured $16m in Seed capital to develop its artificial intelligence-based technology focused on slowing down ageing processes.
Shift Bioscience Funding and Investors
The current round by which has raised the total funding of the company $18M was with the support of BGF as the lead investor with other investors from previous rounds, namely F-Prime Capital, Kindred Capital, and Jon Milner.
Shift Bioscience's Vision: AI and Aging
Shift Bioscience is a data-driven company that has noticed by its CEO Dr. Daniel Ives, using generative AI models to advance human health by redefining aging. Its groundbreaking AI cell simulation platform will allow identifying which genes can rejuvenate certain cells without harming them, thus fighting age-related diseases.
Introduction of Key Features of Shift Bioscience’s AI Platform
- AI-Driven Gene Prediction: They apply generative AI and a biological aging clock to predict the genes that can help rejuvenate cells.
- Testing and Validation: Hold predictions are building, refining and experimenting, and it is done in order to test the predictions for safety and effectiveness.
- Combatting Age-Related Illnesses: This platform is designed for finding out the method of halting cell aging, which means that the treatment of age-related diseases may be significantly changed.
Publications, Citation Analysis and the Realm of Science
The preliminary data obtained using Shift Bioscience’s platform was considered well at the 2024 conference Gordon Research Conference on Systems Aging where the platform is expected to help in the processes of anti-aging research.
Use of Funds
The $16M seed funding will enable Shift Bioscience to:
- Expand the AI cell simulation platform it had developed in the previous year.
- Part of this deluge of research entails identifying the critical genes that should be targeted spectacularly to rejuvenate such cells safely and effectively.
- This study should be advanced to incorporate discovery of diseases associated with aging in order to specifically target treatments to the cells.
From Innovation Start Player to Collaborator : A New Direction for Shift Bioscience
While companies are still trying to find ways to address diseases associated with aging, Shift Bioscience is ready and using artificial intelligence models to demystify aging and cell regeneration. If they decide to keep funding and enhancing their platform, they could become the market’s pioneers in the war against the aging process and regenerative medicine.
**To get all UK Startup news Please Visit – https://growwseed.com/category/uk-startup-funding-news/
